● Publication
Reversal of Malignant ADAR1 Splice Isoform Switching with Rebecsinib

Source
Published
Summary
This landmark study identifies ADAR1p150 splice isoform switching as a key driver of leukemia stem cell (LSC) self-renewal and therapeutic resistance across 20 cancers.
Researchers developed lentiviral ADAR1 reporters, a quantitative intracellular ADAR1p150 assay, and validated Rebecsinib—a selective small-molecule splicing inhibitor that blocks malignant ADAR1 activation.
Key results:
-
Mechanism: Inflammatory microenvironments drive ADAR1p110 → ADAR1p150 switching, fueling cancer progression.
-
Innovation: Rebecsinib inhibits ADAR1p150-driven malignant RNA editing while sparing normal hematopoietic stem/progenitor cells (HSPCs).
-
Preclinical validation: In humanized mouse models, Rebecsinib reduced LSC self-renewal and improved survival.
-
Clinical readiness: Pre-IND studies showed scalable chemistry, favorable pharmacokinetics, and safety across rat, rabbit, and non-human primates.
Together, the findings establish Rebecsinib as a first-in-class ADAR1 pathway antagonist with potential to prevent relapse and resistance in AML, myelofibrosis, and other ADAR1-driven malignancies.



